These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Some quantitative behavioural changes in L-dopa therapy. Meier MJ; Baker AB; Martin WE Trans Am Neurol Assoc; 1970; 95():64-8. PubMed ID: 5514413 [No Abstract] [Full Text] [Related]
45. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
46. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here? Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487 [No Abstract] [Full Text] [Related]
47. [Our experience with the treatment of Parkinson's disease with L-dopa]. Buscaino GA; Campanella G Acta Neurol (Napoli); 1971; 26(1):46-60. PubMed ID: 5553941 [No Abstract] [Full Text] [Related]
48. Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085. Pakkenberg H; Jensen I Adv Neurol; 1983; 37():151-7. PubMed ID: 6344587 [TBL] [Abstract][Full Text] [Related]
49. Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Sweet RD; Lee JE; Speigel HE; McDowell F Neurology; 1972 May; 22(5):520-5. PubMed ID: 4673448 [No Abstract] [Full Text] [Related]
50. [Use of procaine chlorhydrate in arteriosclerotic patients and mental functions]. Colucci D'Amato F; Rogliani G; Feis P Acta Neurol (Napoli); 1975; 30(5):510-4. PubMed ID: 779410 [No Abstract] [Full Text] [Related]
51. Controlled studies of antiparkinsonism agents in the treatment of drug-induced extrapyramidal sympttoms. Simpson GM Acta Psychiatr Scand Suppl; 1970; 212():44-51. PubMed ID: 4917971 [No Abstract] [Full Text] [Related]
52. [Evaluation of the mental state of the elderly patient]. Perlado F Rev Clin Esp; 1988 Oct; 183(5):267-72. PubMed ID: 3212253 [No Abstract] [Full Text] [Related]
53. [Senile mental deterioration: therapeutic aspects]. Tàmmaro AE; Noto M; Mulè M; Bonaccorso O Clin Ter; 1975 Jan; 72(1):55-65. PubMed ID: 776497 [No Abstract] [Full Text] [Related]
54. Hallucinogenic drugs: influence of mental set and setting. Faillace LA; Szara S Dis Nerv Syst; 1968 Feb; 29(2):124-6. PubMed ID: 4866514 [No Abstract] [Full Text] [Related]
55. Prescription charges for levodopa. Liversedge LA Br Med J; 1973 Jul; 3(5872):175. PubMed ID: 4720784 [No Abstract] [Full Text] [Related]
56. [Psychopharmacologic aspects of a stimulant of mental functions, phenylpyrrolidinopentane]. Servais J; Hubin P Rev Med Liege; 1967 Jun; 22(12):350-3. PubMed ID: 4891682 [No Abstract] [Full Text] [Related]
57. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Fuller RLM; Sánchez-Ferro Á; Goetz CG; Martinez-Martin P; Stebbins GT Mov Disord; 2021 Jan; 36(1):270-271. PubMed ID: 33492790 [No Abstract] [Full Text] [Related]